Grace Therapeutics, Inc. Total Assets
Grace Therapeutics, Inc. total assets. Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) holds total assets worth $68.49 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Grace Therapeutics, Inc. (GRCE) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Grace Therapeutics, Inc. (2010–2025)
Total assets of Grace Therapeutics, Inc. from 2010 to 2025. This chart illustrates how Grace Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See Grace Therapeutics, Inc. stock price for real-time trading data and today's change.
Grace Therapeutics, Inc. - Asset Composition Analysis
Grace Therapeutics, Inc. Total Assets Breakdown (March 2025)
Grace Therapeutics, Inc. total assets breakdown as of March 2025. Grace Therapeutics, Inc.'s total assets of $68.49 Million consist of 31.6% current assets and 68.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.7% |
| Accounts Receivable | $126.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $41.13 Million | 57.1% |
| Goodwill | $8.14 Million | 11.3% |
Asset Composition Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Grace Therapeutics, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Grace Therapeutics, Inc.'s current assets represent 31.6% of total assets in 2025, an increase from 9.7% in 2010.
- Cash Position: Cash and equivalents constituted 30.7% of total assets in 2025, up from 4.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 68.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 57.1% of total assets.
Grace Therapeutics, Inc. Competitors by Total Assets
Key competitors of Grace Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Grace Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.96 | 6.06 | 39.50 |
| Quick Ratio | 14.96 | 6.06 | 39.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.93 Million | $9.97 Million | $60.79 Million |
Grace Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Grace Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.55 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | $71.99 Million |
| Market Capitalization | $28.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Grace Therapeutics, Inc.'s assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Grace Therapeutics, Inc.'s assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual total assets of Grace Therapeutics, Inc. from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $71.99 Million | -1.78% |
| 2024-03-31 | $73.30 Million | -7.36% |
| 2023-03-31 | $79.12 Million | -38.48% |
| 2022-03-31 | $128.62 Million | +105.93% |
| 2021-03-31 | $62.46 Million | +173.30% |
| 2020-03-31 | $22.85 Million | -38.06% |
| 2019-03-31 | $36.90 Million | +107.53% |
| 2018-03-31 | $17.78 Million | -15.52% |
| 2016-03-31 | $21.04 Million | -29.24% |
| 2015-03-31 | $29.74 Million | -27.49% |
| 2014-03-31 | $41.01 Million | +244.99% |
| 2013-03-31 | $11.89 Million | -24.86% |
| 2012-03-31 | $15.82 Million | +42.85% |
| 2011-03-31 | $11.07 Million | +24.43% |
| 2010-03-31 | $8.90 Million | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more